Table 1.
Patient Characteristics and Recent (in the Previous 6 Months) Risk Behavior Reported at the Time of Sustained Virologic Response (Baseline) and at the End of Follow-up
| Characteristic | At Sustained Virologic Response | At the End of Follow-up | |
|---|---|---|---|
| At Visit Prior to Reinfection | At Visit Prior to Censoring (Without Reinfection) | ||
| (n = 257) | (n = 18) | (n = 239) | |
| Follow-up in years, median (IQR) |
– | 2.5 (1.6, 3.2) | 1.4 (0.6, 3.2) |
| Demographics and risk behaviors | |||
| Age in years, median (IQR) | 49 (43, 53) | 48 (42, 54) | 51 (45, 56) |
| Male sex, % | 82 | 89 | 82 |
| Aboriginal ethnicity, % | 8 | 11 | 8 |
| Ever IDU, % | 74 | 72 | 74 |
| Type of recent IDU, % a,b | |||
| No IDU | 86 | 50 | 86 |
| Low frequency | 3 | 6 | 2 |
| High frequency | 11 | 44 | 12 |
| Recent shared IDU equipment, % a | 0 | 0 | 1 |
| Recent men who have sex with men activity, % a,c,d | 33 | 40 | 29 |
| Recent condom use, % a,d | |||
| Not sexually active | 43 | 50 | 47 |
| Always | 32 | 25 | 28 |
| Sometimes or never | 25 | 25 | 25 |
| Recent sexually transmitted infection diagnosis, % a,d | 3 | 11 | 4 |
| Clinic type, % | |||
| Tertiary care | 79 | 72 | 80 |
| Community based | 17 | 28 | 16 |
| Rural | 4 | 0 | 4 |
| HIV characteristics | |||
| Time since HIV diagnosis in years, median (IQR) | 15 (9, 22) | 19 (12, 24) | 17 (12, 23) |
| CD4 cell count in cells/µL, median (IQR) d | 450 (310, 640) | 465 (350, 590) | 540 (390, 750) |
| HIV viral load >50 copies/mL, % d | 13 | 28 | 8 |
| On antiretroviral therapy, % | 92 | 72 | 95 |
| HCV characteristics | |||
| Duration of HCV infection in years, median (IQR) | 21 (12, 29) | 21 (13, 28) | 24 (15, 31) |
| HCV genotype at initial infection, % e | |||
| 1 | 62 | 44 | 63 |
| 2 | 8 | 17 | 7 |
| 3 | 20 | 28 | 20 |
| 4 | 2 | 0 | 2 |
| Unknown | 8 | 11 | 8 |
| IL-28B haplotype, % | |||
| CC | 41 | 56 | 40 |
| CT | 27 | 22 | 27 |
| TT | 9 | 5 | 9 |
| Unknown | 23 | 17 | 24 |
| Median AST to platelet ratio index (IQR) | 0.42 (0.31, 0.71) | 0.38 (0.25, 0.51) | 0.40 (0.30, 0.55) |
| Cirrhosis, % | 21 | 28 | 23 |
| HCV treatment, % | |||
| Interferon-free | 20 | 0 | 21 |
Canadian Co-infection Cohort, n = 257.
Abbreviations: AST, aspartate aminotransferase; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IDU, injection drug use; IQR, interquartile range.
aPatient reported behavior for the previous 6 months.
bHigh frequency: patient reported injecting cocaine or methamphetamines. Low frequency: patient reported injecting some other drug.
cAmong males only (n = 212).
dNotes on missing data: Recent men who have sex with men: at baseline, 3; at end of follow-up, 1 of those reinfected, 2 of those censored. Recent condom use: at baseline, 9; at end of follow-up, 2 of those reinfected, 5 of those censored. Recent sexually transmitted infection: at baseline, 6; at end of follow-up, 5 of those censored. CD4 cell count: at baseline, 4; at end of follow-up, 6 of those censored. HIV viral load: at baseline, 8; at end of follow-up, 7 of those censored.
ePrior to HCV treatment.